Trinity Biotech plc (NASDAQ:TRIB) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 579,200 shares, an increase of 103.8% from the December 15th total of 284,200 shares. Based on an average trading volume of 108,100 shares, the short-interest ratio is presently 5.4 days.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LPL Financial LLC raised its stake in Trinity Biotech by 48.3% during the 3rd quarter. LPL Financial LLC now owns 89,073 shares of the company’s stock worth $192,000 after acquiring an additional 29,000 shares during the period. Millennium Management LLC bought a new stake in Trinity Biotech during the 3rd quarter worth approximately $139,000. Morgan Stanley raised its stake in Trinity Biotech by 40.0% during the 3rd quarter. Morgan Stanley now owns 20,765 shares of the company’s stock worth $45,000 after acquiring an additional 5,932 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Trinity Biotech during the second quarter valued at approximately $32,000. Finally, Wealthsource Partners LLC bought a new stake in shares of Trinity Biotech during the third quarter valued at approximately $65,000. Institutional investors own 26.39% of the company’s stock.
NASDAQ TRIB opened at $1.39 on Friday. Trinity Biotech has a 12 month low of $1.21 and a 12 month high of $6.82. The stock has a market cap of $28.95 million, a price-to-earnings ratio of -8.66 and a beta of 1.45. The company’s 50 day moving average is $1.68 and its two-hundred day moving average is $2.08.
About Trinity Biotech
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.
Further Reading: What are defining characteristics of a correction?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.